Plain-English translation of NCT05011383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing whether high-dose testosterone (called BAT in the trial) can help men whose advanced prostate cancer has become resistant to standard hormone-blocking drugs. The study focuses on men whose cancer has specific genetic changes—in genes called ATM, CDK12, or CHEK2—which may make this medication more effective. Participants will receive the medication until their cancer progresses or they cannot tolerate it anymore.
Most men with advanced prostate cancer are given drugs that lower testosterone, but eventually their cancer stops responding to these treatments. Researchers believe that for men whose cancers have certain genetic mutations, giving high doses of testosterone might work differently and help slow or stop cancer growth.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive high-dose testosterone as a treatment, either by injection or another form, while continuing your regular hormone-blocking therapy. You will have frequent visits to the clinic for safety checks, blood tests, and scans (bone scans and CT scans) to see how your cancer is responding. You will continue this treatment for as long as it is working and you can tolerate it without serious side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States